ABK Biomedical combines the clinical market with biomaterials with a focus on treating hypervascular tumors.
ABK Biomedical has raised $35.0M in total funding. The most recent round was Series D. The last funding was announced in October 2025.
ABK Biomedical's investors include Sante Ventures, JP Morgan, F-Prime, Eight Roads Ventures, Innovacorp.
ABK Biomedical is headquartered in Halifax, Canada.
ABK Biomedical combines the clinical market with biomaterials with a focus on treating hypervascular tumors.
ABK Biomedical is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ABK Biomedical — Funding & Investors." VCBacked, October 14, 2025, https://www.vcbacked.co/company/abk-biomedical. Accessed July 20, 2026.
VCBacked. (2025). ABK Biomedical — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/abk-biomedical
{{cite web |title=ABK Biomedical — Funding & Investors |url=https://www.vcbacked.co/company/abk-biomedical |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated